Page 100 - Genentech News Today

BioPharma

The immunotherapy agent atezolizumab induces sustained responses in about one-third of patients with advanced alveolar soft part sarcoma (ASPS).

FCS Director of Drug Development Manish Patel, MD Co-Authors BothFORT MYERS, Fla., Sept. 15, 2023 /PRNewswire/ -- Florida Cancer Specialists & Res...

Atezolizumab produced sustained responses in more than a third of patients with alveolar soft part sarcoma in a phase 2 trial.

Jasmax is one of New Zealand’s leading architecture and design practices.

The LEAP-017 trial results presented at ESMO GI 2023 are explored by Dr Marshall.

CARLSBAD, Calif.--(BUSINESS WIRE)--Sep 13, 2023--

The frequency with which 7 of the largest Medicare Advantage plans impose step therapy protocols in their Part B drug coverage decisions varies substantially.

Antibody treatments may be able to activate the immune system to fight diseases like Parkinson's, Alzheimer's and colorectal cancer, but they are less effective when they bind with themselves and other molecules that aren't markers of disease.

The Biden administration just announced a new initiative to improve cancer outcomes in low-income communities across the United States. It marks a critical step toward meeting the broader goals of